Expansion of Biomedical Research On The Cards In Australia

Monash University- Australia has gone on to buy a prominent Parkville property that will go on to become a major addition to its campus, which is home to the world-leading Faculty of Pharmacy and Pharmaceutical Sciences, and thereby unprecedentedly advance the capabilities of Australia’s biomedical research so as to drive the discovery as well as the development of new medicines.

The said property, which was previously owned by the Commonwealth Scientific and Industrial Research Organization- CSIRO, which is the country’s national science agency, is all set to get refurbished in order to offer further space when it comes to the broadening of top-notch amenities for the Monash Institute of Pharmaceutical Sciences- MIPS.

It is well to be noted that MIPS happens to be a world-leading institute that has a focus on research that pushes the exploration as well as the development of new and enhanced drugs and also elevates the safe and impactful use of medicines. Professor Margaret Gardner, AC, the President, and the VC opined that the property will surely become a research hub for an array of major priority areas.

This will thereby help in the expansion of activities when it comes to drug candidate optimisation, medicinal chemistry, and drug formulation that will help in supporting the translation of breakthrough biology into advanced preclinical as well as clinical drug candidates that are apt for commercial progression.

It will also go on to enable the development and expansion of the recent focus areas for Monash that range from next-gen neuromedicines to mRNA therapeutics, innovative mechanisms of drug screening, as well as structure-based drug design.